chitosan siRNA nanoparticles (ANRis)

N/A

Report date: 2026/05/12 20:00:17
NME

Base Information

Drug Namechitosan siRNA nanoparticles (ANRis)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionDipeptidyl peptidase IV inhibitorsGlucagon-like peptide 1 receptor agonists
TargetsDipeptidyl peptidase IVGlucagon-like peptide 1 receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesANRis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesANRis Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A